Clinical Feasibility of the Myotrace Measurement

Inclusion Criteria:

• Age 18+, fluent knowledge of English or German.

• Group A: Obstructive ventilatory disorders (conditions resulting in an increasedload on the respiratory muscle pump due to hyperinflation ± pronounced hypoxaemia)

• Acute exacerbation of COPD (pronounced hypoxia OR acute or acute on chronichypercapnic respiratory failure)

• Exacerbation of asthma bronchiale

• Exacerbation of non-CF-bronchiectasis (infectious)

• Infectious exacerbation of lung disease in cystic fibrosis

• Group B: Conditions with an increase in NRD due to an impairment in gas exchange (particularly die to diffusion limitation and/or ventilation-perfusion-mismatch

• Exacerbation of an interstitial lung disease (e.g. Idiopathic pulmonaryfibrosis (IPF), Non Specific Interstitial Pneumonia (NSIP), Connective tissuedisease- associated interstitial lung disease CTD-ILD)

• Worsening of pulmonary arterial hypertension World Health Organisation (WHO)group 1 (e.g. due decompensated heart failure)

• Acute pulmonary embolism

• Pneumonia (resulting in hypoxaemia)

Exclusion Criteria:

• Obesity hypoventilation syndrome (rationale: NRD decreased)

• Obesity WHO III with Body Mass Index (BMI) > 40 kg/m2 (rationale: surface EMG signalquality low)

• Hypercapnic respiratory failure due to hypoventilation of central origin, e.g.opiate-induced, Congenital central hypoventilation syndrome, post stroke (rationale:central respiratory control affected)

• Neuromuscular disease affecting respiratory muscles, e.g. motor neurone disease,muscular dystrophy type Duchenne etc. (rationale: EMG signal quality etc. different)

• Decompensated heart failure with atrial fibrillation (rationale: central breathingdisturbance common)

• Patients on chronic opioid therapy (e.g. chronic pain, methadone etc.) (rationale:reduced NRD)

• Self reported pregnancy